Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
- VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - ...
Neurizon Therapeutics Limited , a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is ...
Lilly to Develop Two Targets Identified and Validated Using ’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of ...
amyotrophic lateral sclerosis (ALS). The latter condition – also known as Lou Gehrig’s disease – causes damage to the nerve ...
A new AI-powered interpreter is expected to simulate speakers’ voices in different languages during Microsoft Teams meetings.
Alabama Governor Kay Ivey released a statement following the death of former State Finance Director Kelly Butler.Ivey said ...
The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...
The St. Peter’s Hospital ALS Regional Center gives specialized services and resources to people with Amyotrophic Lateral ...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...
Biopharmaceutical company Trace Neuroscience announced it has raised $101 million in a Series A financing effort to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback